ClinicalTrials.gov
public full text
Public Domain
Oral Omega-3 Fatty Acids in the Treatment of Dry Eye Syndrome
The investigators hypothesize that oral omega-3-acid ethyl esters (Lovaza, GlaxoSmithKline, Research Triangle Park, NC) will decrease dry-eye related symptoms as well as clinical markers associated with dry eye disease (Schirmer-1 test values, positive vital staining with lissamine green, and fluorescein tear break-up time) when compared to administration of placebo.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Omega-3 Fatty Acid Supplements and Dry Eye#1163306
- Effect of an Oral Supplement Containing Omega-3 and Omega-6 on Dry Eye Symptoms#1057389
- Effect of Omega-3 Fatty Acid Supplementation on Dry-AMD Progression#826658
- Fish Oil to Prevent Asthma Exacerbations in Patients With ALOX5 Polymorphisms#1046712
- Effect of a Dietary Supplement on Gut Microbiota and Ocular Surface Outcomes in Dry Eye Disease#914556
Record · ID 1138371
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive